---
title: "Descartes-08 in Generalized myasthenia gravis: Mechanism of action"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Mechanism of action. Topics: Transient CAR expression from RNA without genomic modification, CAR-positive cell load limited by the administered dose, Target antigen: BCMA on plasma cells, Proposed mechanism: preferential depletion of BCMA-high plasma cells and a precision immune reset, and 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Transient CAR expression from RNA without genomic modification

> “Engineering of cells using RNA offers distinct advantages toward this goal by exploiting transient CAR expression.”
> “This characteristic enables dosing at levels that are immediately therapeutic and that exhibit a built-in proliferative check: CAR RNA degrades during cell division.”
> “As a result, RNA cell therapy can be administered without lymphodepletion and in the outpatient setting, also eliminating the risk of secondary malignancies because no genomic modification occurs.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

> “Unlike DNA, mRNA degrades naturally over time without integrating into the cell’s genetic material.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.1.2.6.1-2"></a>

### CAR-positive cell load limited by the administered dose

> “Since the CAR-encoding mRNA does not replicate together with the activated and proliferating rCAR T-cells, the load of CAR+ cells is determined and limited by the administered dose, and declines over time, potentially enabling more precise PK control over the therapy.”
> “Because our approach uses ex vivo T-cell proliferation, it does not require the specific cytokine environment induced by lymphodepletion.”
> “Only CD8+ T-cells are used for manufacturing since CD4+ T-cells are known for their memory function, rather than direct killing function, which is not relevant to RNA-transfected CAR T-cells that express the CAR molecule over days.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-2.1.2.6.1-3"></a>

### Target antigen: BCMA on plasma cells

> “BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival.”

Source: [NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-bcma-car-mrna-transfected-cd8-t-lymphocytes)

> “Descartes-08 targets BCMA+ cells, among which PCs and pDCs are most abundant9; these are also populations involved in autoimmune pathogenicity, including PCs that produce autoantibodies in MG37.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.6.1-4"></a>

### Proposed mechanism: preferential depletion of BCMA-high plasma cells and a precision immune reset

> “Potential mechanisms could involve precision ablation (for example, direct cytotoxicity) or interference (for example, trogocytosis) on the BCMAhi subset comprising pathogenic PCs and other cells such as pDCs.”
> “Functionally, therefore, Descartes-08 may preferentially deplete PCs expressing high levels of BCMA, which, in patients with autoimmune disease, is preferential to PCs producing pathogenic autoantibodies.”
> “Directly testing these hypotheses is a clinical challenge in the context of autoimmunity because the key target cells are predominantly located outside of circulation—PCs resident in the bone marrow and activated pDCs and B cells in inflamed tissue or lymphatics11,37,41–43.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.6.1-5"></a>

### Mechanism compared with complement inhibitors, FcRn inhibitors, and DNA-based CAR-T cell therapies

> “These technologies include FcRn inhibitors and complement inhibitors that directly target circulating antibodies and antibody effector function, respectively; both technologies involve ongoing treatment to maintain effect48–50.”
> “Further, emerging T cell therapies often involve lymphodepletion, viral vectors and targeting of CD19 that result in non-specific depletion of B cells and, consequently, immunoglobulins and vaccine titers2,45,46.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
